Ningbo Menovo Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 603538.SS

Ningbo Menovo Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2023: USD -30.92 M

Ningbo Menovo Pharmaceutical Co., Ltd. Capital Expenditure is USD -30.92 M for the year ending December 31, 2023, a 62.67% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Ningbo Menovo Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2022 was USD -82.83 M, a 0.67% change year over year.
Ningbo Menovo Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2021 was USD -83.39 M, a -74.62% change year over year.
Ningbo Menovo Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2020 was USD -47.76 M, a -1.38% change year over year.
Ningbo Menovo Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2019 was USD -47.11 M, a -8.15% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Shanghai Stock Exchange: 603538.SS

Ningbo Menovo Pharmaceutical Co., Ltd.

CEO	Mr. Cheng Zhi Yao
IPO Date	April 10, 2017
Location	China
Headquarters	Building1,Ningbo R&D Park
Employees	2,353
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. It offers APIs, intermediates, and formulations for the treatment of cardiovascular, central nervous, respiratory, antitumor, anti-infection, digestive, and geriatric diseases, as well as antiviral. The company was founded in 2004 and is headquartered in Ningbo, China.

Key trends

Past 5 years